Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 4/20 | 0.39 |
| ▸ | PTGES | O14684 | 3/20 | 0.39 |
| ▸ | PPARG | P37231 | 3/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | PPARA | Q07869 | 1/20 | 0.36 |
| ▸ | CYP4Z1 | Q86W10 | 1/20 | 0.36 |
| ▸ | TNF | P01375 | 1/20 | 0.35 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.35 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.35 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4547668 | 0.93 | ALOX5 (0.40) | ALOX5PTGESPPARGCYP1A2KMT2A | |
| SCHEMBL2676202 | 0.84 | PTGES (0.35) | ALOX5PTGESPPARGCYP1A2KMT2A | |
| SCHEMBL4550957 | 0.81 | CYP4Z1 (0.37) | ALOX5CYP1A2KMT2ACYP4Z1TNF | |
| SCHEMBL9442220 | 0.77 | FOLH1 (0.48) | ALOX5PTGESPPARGCYP1A2KMT2A | |
| SCHEMBL4547657 | 0.75 | CYP1A2 (0.40) | CYP1A2KMT2ACYP4Z1TNFCYP4F2 | |
| SCHEMBL2295351 | 0.75 | FOLH1 (0.46) | ALOX5PTGESPPARGPPARAFOLH1 | |
| SCHEMBL2302006 | 0.74 | CYP4F2 (0.54) | ALOX5CYP1A2CYP4Z1CYP4F2CYP4A11 | |
| SCHEMBL4547658 | 0.74 | CYP1A2 (0.39) | CYP1A2KMT2ACYP4Z1TNFCYP4F2 | |
| SCHEMBL13629652 | 0.73 | CHRM1 (0.47) | ALOX5PTGESPPARGCYP1A2PPARA | |
| SCHEMBL14360165 | 0.72 | CA2 (0.53) | CYP1A2KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8173704-B2 | Difluorophenol derivatives and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-05-08 | — | — | US | disclosed |
| US-20090291993-A1 | Difluorophenol Derivatives and Their Use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2009-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291993-A1 | Difluorophenol Derivatives and Their Use | TPMT, FABP3, DPP4 | ALOX5 1580/4885PTGES 1662/4885PPARG 73/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.